RU2017137366A3 - - Google Patents

Download PDF

Info

Publication number
RU2017137366A3
RU2017137366A3 RU2017137366A RU2017137366A RU2017137366A3 RU 2017137366 A3 RU2017137366 A3 RU 2017137366A3 RU 2017137366 A RU2017137366 A RU 2017137366A RU 2017137366 A RU2017137366 A RU 2017137366A RU 2017137366 A3 RU2017137366 A3 RU 2017137366A3
Authority
RU
Russia
Application number
RU2017137366A
Other languages
Russian (ru)
Other versions
RU2017137366A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017137366A publication Critical patent/RU2017137366A/ru
Publication of RU2017137366A3 publication Critical patent/RU2017137366A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2017137366A 2015-03-26 2016-03-25 Конденсированные бициклические соединения для лечения заболевания RU2017137366A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562138725P 2015-03-26 2015-03-26
US62/138,725 2015-03-26
PCT/IB2016/000606 WO2016151403A1 (en) 2015-03-26 2016-03-25 Fused bicyclic compounds for the treatment of disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021107054A Division RU2021107054A (ru) 2015-03-26 2016-03-25 Конденсированные бициклические соединения для лечения заболевания

Publications (2)

Publication Number Publication Date
RU2017137366A RU2017137366A (ru) 2019-04-26
RU2017137366A3 true RU2017137366A3 (enExample) 2019-07-17

Family

ID=56072361

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2021107054A RU2021107054A (ru) 2015-03-26 2016-03-25 Конденсированные бициклические соединения для лечения заболевания
RU2017137366A RU2017137366A (ru) 2015-03-26 2016-03-25 Конденсированные бициклические соединения для лечения заболевания

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2021107054A RU2021107054A (ru) 2015-03-26 2016-03-25 Конденсированные бициклические соединения для лечения заболевания

Country Status (16)

Country Link
US (4) US10421759B2 (enExample)
EP (2) EP3715348A1 (enExample)
JP (1) JP6843061B2 (enExample)
KR (1) KR20180003545A (enExample)
CN (1) CN107912042A (enExample)
AU (2) AU2016238523A1 (enExample)
BR (1) BR112017020374A2 (enExample)
CA (1) CA2980394A1 (enExample)
CL (1) CL2017002405A1 (enExample)
CO (1) CO2017010621A2 (enExample)
HK (1) HK1249756A1 (enExample)
IL (1) IL254572A0 (enExample)
MX (1) MX370897B (enExample)
RU (2) RU2021107054A (enExample)
SG (2) SG10201908881PA (enExample)
WO (1) WO2016151403A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016151403A1 (en) * 2015-03-26 2016-09-29 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
EP3463373A4 (en) * 2016-05-25 2020-04-22 Akarna Therapeutics, Ltd. COMBINATION THERAPIES WITH FARNESOID-X RECEPTOR (FRX) MODULATORS
BR112018074231A2 (pt) * 2016-05-25 2019-03-06 Akarna Therapeutics, Ltd. compostos bicíclicos fundidos para o tratamento de doença
WO2018222876A1 (en) * 2017-06-02 2018-12-06 Akarna Therapeutics, Ltd. Fused bicyclic compounds
CN108264474B (zh) * 2018-02-09 2019-10-25 浙江师范大学 一种色胺及其衍生物的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
CA2532798C (en) * 2003-07-23 2013-02-19 X-Ceptor Therapeutics Inc. Azepine derivatives as pharmaceutical agents
BRPI0514269A (pt) 2004-08-10 2008-06-10 Exelixis Inc compostos heterocìclicos como agentes farmacêuticos
WO2006109633A1 (ja) 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
CA2633243C (en) * 2005-12-15 2014-05-27 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
WO2008073825A1 (en) 2006-12-08 2008-06-19 Exelixis, Inc. Lxr and fxr modulators
US20090131409A1 (en) 2007-10-22 2009-05-21 Wyeth 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
US20090137554A1 (en) 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
WO2010036362A1 (en) * 2008-09-26 2010-04-01 Wyeth 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
ES2911293T3 (es) * 2014-11-21 2022-05-18 Akarna Therapeutics Ltd Compuestos bicíclicos fusionados para el tratamiento de enfermedades
JP2017538773A (ja) * 2014-12-22 2017-12-28 アカーナ・セラピューティクス・リミテッドAkarna Therapeutics, Ltd. 疾患の処置のための縮合二環式化合物
WO2016151403A1 (en) * 2015-03-26 2016-09-29 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease

Also Published As

Publication number Publication date
MX2017012342A (es) 2018-06-11
RU2021107054A (ru) 2021-03-31
JP6843061B2 (ja) 2021-03-17
MX370897B (es) 2020-01-09
AU2016238523A1 (en) 2017-11-09
EP3715348A1 (en) 2020-09-30
CN107912042A (zh) 2018-04-13
US10421759B2 (en) 2019-09-24
SG10201908881PA (en) 2019-11-28
RU2017137366A (ru) 2019-04-26
IL254572A0 (en) 2017-11-30
CO2017010621A2 (es) 2018-01-31
CL2017002405A1 (es) 2018-04-27
CA2980394A1 (en) 2016-09-29
US20180118752A1 (en) 2018-05-03
US20200079782A1 (en) 2020-03-12
WO2016151403A1 (en) 2016-09-29
SG11201707610PA (en) 2017-10-30
JP2018510876A (ja) 2018-04-19
AU2020256301A1 (en) 2020-11-05
US20210214362A1 (en) 2021-07-15
US20230002394A1 (en) 2023-01-05
HK1249756A1 (zh) 2018-11-09
EP3274350A1 (en) 2018-01-31
KR20180003545A (ko) 2018-01-09
BR112017020374A2 (pt) 2018-06-05

Similar Documents

Publication Publication Date Title
BE2015C044I2 (enExample)
BR0000126B1 (enExample)
CN303069816S (enExample)
BR0009761B1 (enExample)
BR0006634B1 (enExample)
BR0008874B1 (enExample)
CN303065935S (enExample)
BR0000763F1 (enExample)
CN303066642S (enExample)
BR0008132B1 (enExample)
BR0002874B1 (enExample)
BR0002033B1 (enExample)
BR0008789B1 (enExample)
BR0007834B1 (enExample)
BR0009942B1 (enExample)
BR0003686B1 (enExample)
BR0212083B1 (enExample)
BR0002802B1 (enExample)
BR0204702B1 (enExample)
BR0005085B1 (enExample)
BR0007688B1 (enExample)
BR0006866B1 (enExample)
BR0007487B1 (enExample)
BR0000695B1 (enExample)
BR0003751B1 (enExample)